LONDON--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, and NHS England today announced the availability of the easy ...

EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the publication of a ...

Dexcom has been abuzz this year amid the European approval—and submission for FDA approval in the U.S.—for its next-generation G7 continuous glucose monitoring system, which promises more accurate ...

Dexcom has launched its ONE+ continuous glucose monitoring (CGM) device in the UK, alongside a report that details high rates of anxiety and depression amongst type 2 diabetes (T2D) patients. The ...

Partnership will enable two-way data flow between Dexcom glucose biosensors and apps and Oura Ring and the Oura App, providing a first-of-its-kind metabolic health management experience Co-marketing ...

SAN DIEGO--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today its next-generation Dexcom G7 CGM System ...

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM) (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will ...